Eaton Vance Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $614M | Buy |
1,210,607
+29,401
| +2% | +$16.5M | 0.91% | 15 |
|
|
2022
Q2 | $642M | Buy |
1,181,206
+72,935
| +7% | +$40.1M | 0.9% | 15 |
|
|
2022
Q1 | $655M | Buy |
1,108,271
+249,328
| +29% | +$143M | 0.75% | 21 |
|
|
2021
Q4 | $573M | Sell |
858,943
-45,109
| -5% | -$28.2M | 0.7% | 25 |
|
|
2021
Q3 | $514M | Buy |
904,052
+14,896
| +2% | +$8.18M | 0.71% | 26 |
|
|
2021
Q2 | $449M | Buy |
889,156
+84,666
| +11% | +$39.9M | 0.61% | 29 |
|
|
2021
Q1 | $367M | Sell |
804,490
-11,546
| -1% | -$5.51M | 0.54% | 31 |
|
|
2020
Q4 | $380M | Buy |
816,036
+148,429
| +22% | +$69.6M | 0.6% | 31 |
|
|
2020
Q3 | $295M | Sell |
667,607
-7,996
| -1% | -$3.3M | 0.54% | 39 |
|
|
2020
Q2 | $245M | Buy |
675,603
+164,183
| +32% | +$55M | 0.5% | 41 |
|
|
2020
Q1 | $145M | Buy |
511,420
+7,966
| +2% | +$2.51M | 0.35% | 63 |
|
|
2019
Q4 | $164M | Sell |
503,454
-12,215
| -2% | -$3.7M | 0.32% | 79 |
|
|
2019
Q3 | $150M | Buy |
515,669
+14,626
| +3% | +$4.19M | 0.32% | 79 |
|
|
2019
Q2 | $147M | Sell |
501,043
-6,211
| -1% | -$1.71M | 0.32% | 80 |
|
|
2019
Q1 | $139M | Sell |
507,254
-12,103
| -2% | -$3.01M | 0.32% | 80 |
|
|
2018
Q4 | $116M | Buy |
519,357
+32,557
| +7% | +$7.64M | 0.3% | 86 |
|
|
2018
Q3 | $119M | Sell |
486,800
-947
| -0.2% | -$218K | 0.26% | 105 |
|
|
2018
Q2 | $101M | Buy |
487,747
+10,739
| +2% | +$2.28M | 0.24% | 111 |
|
|
2018
Q1 | $98.5M | Sell |
477,008
-35,065
| -7% | -$7.36M | 0.25% | 110 |
|
|
2017
Q4 | $97.2M | Buy |
512,073
+14,026
| +3% | +$2.69M | 0.24% | 111 |
|
|
2017
Q3 | $94.2M | Sell |
498,047
-253,297
| -34% | -$45.9M | 0.24% | 113 |
|
|
2017
Q2 | $131M | Sell |
751,344
-32,202
| -4% | -$5.41M | 0.34% | 80 |
|
|
2017
Q1 | $120M | Sell |
783,546
-12,647
| -2% | -$1.93M | 0.32% | 89 |
|
|
2016
Q4 | $112M | Sell |
796,193
-28,840
| -3% | -$4.25M | 0.32% | 89 |
|
|
2016
Q3 | $131M | Buy |
825,033
+53,577
| +7% | +$8.26M | 0.38% | 77 |
|
|
2016
Q2 | $114M | Sell |
771,456
-107,645
| -12% | -$15.9M | 0.33% | 89 |
|
|
2016
Q1 | $124M | Buy |
879,101
+13,642
| +2% | +$1.83M | 0.38% | 78 |
|
|
2015
Q4 | $123M | Sell |
865,459
-48,999
| -5% | -$6.54M | 0.36% | 80 |
|
|
2015
Q3 | $112M | Buy |
914,458
+37,195
| +4% | +$4.85M | 0.34% | 78 |
|
|
2015
Q2 | $114M | Sell |
877,263
-280,517
| -24% | -$36.6M | 0.35% | 81 |
|
|
2015
Q1 | $156M | Sell |
1,157,780
-82,214
| -7% | -$10.6M | 0.47% | 71 |
|
|
2014
Q4 | $155M | Sell |
1,239,994
-23,876
| -2% | -$2.9M | 0.46% | 65 |
|
|
2014
Q3 | $154M | Sell |
1,263,870
-185,092
| -13% | -$22.5M | 0.46% | 65 |
|
|
2014
Q2 | $171M | Buy |
1,448,962
+239,525
| +20% | +$28.2M | 0.51% | 61 |
|
|
2014
Q1 | $145M | Sell |
1,209,437
-124,550
| -9% | -$14.8M | 0.43% | 72 |
|
|
2013
Q4 | $149M | Sell |
1,333,987
-169,968
| -11% | -$16.9M | 0.43% | 72 |
|
|
2013
Q3 | $139M | Sell |
1,503,955
-91,127
| -6% | -$8.24M | 0.42% | 81 |
|
|
2013
Q2 | $135M | Buy |
+1,595,082
| New | +$133M | 0.41% | 79 |
|
Other funds holding TMO
Eaton Vance Management's TMO Position: Q3 2022 in Review
Eaton Vance Management increased its Thermo Fisher Scientific (TMO) stake by 2.5% in Q3 2022, buying an estimated $16.5M and bringing the position to 1,210,607 shares worth $614M. The position accounts for 0.91% of the portfolio, ranked #15.
Eaton Vance Management first reported a position in TMO in Q2 2013 and has held it in 38 quarters since. The position peaked at $655M in Q1 2022. 2,268 funds tracked by Wall St. Rank hold TMO as of Q3 2022.
- Eaton Vance Management held 1,210,607 shares of Thermo Fisher Scientific worth $614M as of Q3 2022.
- Eaton Vance Management bought 29,401 Thermo Fisher Scientific shares in Q3 2022, an estimated $16.5M.
- Thermo Fisher Scientific made up 0.91% of Eaton Vance Management's portfolio in Q3 2022, its #15 holding.
- Eaton Vance Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Thermo Fisher Scientific position peaked at $655M in Q1 2022.
- 2,268 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.